Objective： Stanniocalcin-1 （STC-1）, a kind of glycoprotein hormone, is universally up-regulated in various tumor tissues compared to corresponding normal tissues, suggesting it may be used as a tumor marker, whilst...Objective： Stanniocalcin-1 （STC-1）, a kind of glycoprotein hormone, is universally up-regulated in various tumor tissues compared to corresponding normal tissues, suggesting it may be used as a tumor marker, whilst disseminated tumor cells usually exist in peripheral blood. The aim of this study is to investigate the mRNA expression STC-1 in peripheral blood of colorectal cancer （CRC） and analyze its clinicopathological significance. Methods： The peripheral blood mononuclear cells （PBMNCs） were isolated from 78 CRC patients and 33 cancer-free controls. The expression status of STC-1 mRNA in PBMNCs was assessed by RT-PCR, its correlation with clinicopathological parameters and 5-year overall survival was analyzed as well. Results： In the 78 blood samples from CRC patients, 33 （42.31%） showed positive expression of STC-1 mRNA, and all of 15 gastrointestinal tumor tissues were positive for STC-1 mRNA. In contrast, all the blood samples from 14 healthy donors and 19 patients with inflammatory gastrointestinal disease were negative. Furthermore, STC-1 mRNA expression status was associated with patients’ advanced stage, distant metastasis and shortened overall survival. Conclusion： The detection of STC-1 mRNA in peripheral blood by RT-PCR was highly sensitive and specific for the patients with CRC. STC-1 mRNA may be a potential biomarker for detecting tumor micrometastasis and predicting prognosis.展开更多
目的探究纤维蛋白原样蛋白1(fibrinogen-like protein 1,FGL1)和膜联蛋白A11(annexin A11,ANXA11)对肺癌手术患者效用评估价值及与预后的相关性。方法将本院2020年1月至2023年12月接诊的98例肺癌患者纳入肺癌组,另选取98例健康人作为对...目的探究纤维蛋白原样蛋白1(fibrinogen-like protein 1,FGL1)和膜联蛋白A11(annexin A11,ANXA11)对肺癌手术患者效用评估价值及与预后的相关性。方法将本院2020年1月至2023年12月接诊的98例肺癌患者纳入肺癌组,另选取98例健康人作为对照组。受试者入院后分别于空腹状态下采取6 mL肘静脉血,采用ELISA法检测血清ANXA11水平,采用实时荧光定量PCR技术检测ANXA11表达水平。根据术后1个月肿瘤标志物变化、影像学表现和免疫功能指标变化情况分为治疗有效组(n=68)和无效组(n=30)。患者出院后均行12~36个月的随访,根据患者预后情况分为预后良好组(n=63)和预后不良组(n=35)。对比对照组和肺癌组/有效组和无效组/预后FGL1、ANXA11表达差异;ROC分析FGL1、ANXA11单一及联合检测对肺癌手术患者临床效用评估价值;Spearman分析FGL1、ANXA11表达与预后的关系。结果肺癌组FGL1和ANXA11表达水平明显高于对照组(均P<0.05);无效组FGL1和ANXA11表达水平明显高于有效组(均P<0.05);ROC结果显示FGL1、ANXA11单独及联合检测对肺癌手术患者效用评估的曲线线下面积分别为0.928,并且联合检测具有较高的特异性(95.59%)以及敏感度(90.00%),诊断价值显著高于单独检测ROC曲线线下面积(均P<0.05);预后不良组FGL1和ANXA11表达水平明显高于预后良好组(均P<0.05);Spearman相关性结果显示FGL1、ANXA11与肺癌手术患者预后呈显著正相关(r=0.771、0.793,均P<0.05)。结论肺癌患者的FGL1与ANXA11表达水平高于健康人,治疗无效者高于有效者,预后不良者高于良好者,二者单独及联合检测对患者手术治疗效用评估均有价值,且其与预后相关性显著。展开更多
基金supported by the grants from the Department of Health, Jiangsu Province, China (No.H200116)
文摘Objective： Stanniocalcin-1 （STC-1）, a kind of glycoprotein hormone, is universally up-regulated in various tumor tissues compared to corresponding normal tissues, suggesting it may be used as a tumor marker, whilst disseminated tumor cells usually exist in peripheral blood. The aim of this study is to investigate the mRNA expression STC-1 in peripheral blood of colorectal cancer （CRC） and analyze its clinicopathological significance. Methods： The peripheral blood mononuclear cells （PBMNCs） were isolated from 78 CRC patients and 33 cancer-free controls. The expression status of STC-1 mRNA in PBMNCs was assessed by RT-PCR, its correlation with clinicopathological parameters and 5-year overall survival was analyzed as well. Results： In the 78 blood samples from CRC patients, 33 （42.31%） showed positive expression of STC-1 mRNA, and all of 15 gastrointestinal tumor tissues were positive for STC-1 mRNA. In contrast, all the blood samples from 14 healthy donors and 19 patients with inflammatory gastrointestinal disease were negative. Furthermore, STC-1 mRNA expression status was associated with patients’ advanced stage, distant metastasis and shortened overall survival. Conclusion： The detection of STC-1 mRNA in peripheral blood by RT-PCR was highly sensitive and specific for the patients with CRC. STC-1 mRNA may be a potential biomarker for detecting tumor micrometastasis and predicting prognosis.
文摘目的探究纤维蛋白原样蛋白1(fibrinogen-like protein 1,FGL1)和膜联蛋白A11(annexin A11,ANXA11)对肺癌手术患者效用评估价值及与预后的相关性。方法将本院2020年1月至2023年12月接诊的98例肺癌患者纳入肺癌组,另选取98例健康人作为对照组。受试者入院后分别于空腹状态下采取6 mL肘静脉血,采用ELISA法检测血清ANXA11水平,采用实时荧光定量PCR技术检测ANXA11表达水平。根据术后1个月肿瘤标志物变化、影像学表现和免疫功能指标变化情况分为治疗有效组(n=68)和无效组(n=30)。患者出院后均行12~36个月的随访,根据患者预后情况分为预后良好组(n=63)和预后不良组(n=35)。对比对照组和肺癌组/有效组和无效组/预后FGL1、ANXA11表达差异;ROC分析FGL1、ANXA11单一及联合检测对肺癌手术患者临床效用评估价值;Spearman分析FGL1、ANXA11表达与预后的关系。结果肺癌组FGL1和ANXA11表达水平明显高于对照组(均P<0.05);无效组FGL1和ANXA11表达水平明显高于有效组(均P<0.05);ROC结果显示FGL1、ANXA11单独及联合检测对肺癌手术患者效用评估的曲线线下面积分别为0.928,并且联合检测具有较高的特异性(95.59%)以及敏感度(90.00%),诊断价值显著高于单独检测ROC曲线线下面积(均P<0.05);预后不良组FGL1和ANXA11表达水平明显高于预后良好组(均P<0.05);Spearman相关性结果显示FGL1、ANXA11与肺癌手术患者预后呈显著正相关(r=0.771、0.793,均P<0.05)。结论肺癌患者的FGL1与ANXA11表达水平高于健康人,治疗无效者高于有效者,预后不良者高于良好者,二者单独及联合检测对患者手术治疗效用评估均有价值,且其与预后相关性显著。
